dan_bradburyDan Bradbury

Co-Founder and Chairman

Dan is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value.  He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm.

Dan is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100.  He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals.  He serves on the board of directors of Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Illumina, Inc. (NASDAQ: ILMN), BioMed Realty (NYSE: BMR), Biocon Limited (NSE: BIOCON), Castle Biosciences, Inc. (Private), DiaVacs (Private) and Microdermis, Inc. (Private). He also serves on the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board and the BioMed Ventures Advisory Committee.

 Dan currently serves on the University of California San Diego’s Rady School of Management's Advisory Council and the University of Miami's Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

MikeMoradi 2Mike Moradi

Co-Founder and CEO

Mr. Moradi is a successful entrepreneur, having founded or been a principal in several Nanotech and biopharma startups. Mike was a co-founder and CEO of an ocular pharmaceutical company and specialty Contract Research Organization (CRO), which was #264 fastest growing private company in the 2009 Inc. 500. He co-founded Southwest Nanotechnologies (“SWeNT”), a world-leading manufacturer of carbon nanotubes, and Nanopolaris (now Unidym), which was acquired in 2011 y a publicly traded South Korean company for $145MM.



HuangDr. Huang Xin

Director and Chairman

Dr. Xin is a Managing Partner of Cowin Venture Capital.  He is a former Senior Investment Manager for Omaha Capital China, and a former consultant for Boston Consulting Group.  He received his PhD from Johns Hopkins University School of Medicine, and is a graduate of Peking Union Medical College and Peking University.



Sensulin News